Understand the source comparison
Follistatin-344 Dosage Comparison: Research Protocols vs Practical Application
Murine muscle hypertrophy models 1–3 mg/kg (70–210 mg for 70 kg human equivalent) Single injection or gene therapy vector Muscle fiber cross-sectional area increase Direct translation to humans fails. Receptor density differs substantially between species Huma
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Murine muscle hypertrophy models
- 1–3 mg/kg (70–210 mg for 70 kg human equivalent)
- Single injection or gene therapy vector
- Muscle fiber cross-sectional area increase
- Direct translation to humans fails. Receptor density differs substantially between species
- Human cachexia trials (Phase I safety)
- 0.5–2.0 mg total dose
- Single IV infusion
- Safety markers, circulating follistatin levels
- Doses above 1 mg showed no added myostatin suppression but increased activin-related adverse events
- Athletic performance research (observational)
- 100–300 mcg daily
- Daily subcutaneous
- Lean body mass change, strength markers
- Most measurable hypertrophy occurred in the 200–300 mcg range. Lower doses showed minimal effect
- Peptide research community protocols
- 100–500 mcg daily
- Daily subcutaneous or every other day
- Subjective recovery, muscle fullness
- Doses above 300 mcg reported no additional benefit but increased reports of joint discomfort (likely activin-mediated)